Sign in

Erick Turner

@eturnermd1.bsky.social
898 followers 218 following 2.5K posts

Advocate for and researcher on transparency in medical research. Former FDA reviewer of psychotropic drugs back when the FDA was a tougher gatekeeper.

PostsRepliesMedia
Erick Turner @eturnermd1.bsky.social · 28/09/2026
“Not as good as a coin toss” but FDA panel recommends multi-cancer test for approval garyschwitzer.substack.com/p/fda-panel-...
garyschwitzer.substack.com
“Not as good as a coin toss” but FDA panel recommends multi-cancer test for approval
To me, this is a head-scratcher.
142
Erick Turner @eturnermd1.bsky.social · 01/09/2026
Every now and then, one of the recent disappointing developments is undone. (Apologies for the lack of full text. This outlet's subscriptions are apparently priced for deep-pocketed drug companies.) insights.citeline.com/pink-sheet/a...
021
Erick Turner @eturnermd1.bsky.social · 28/08/2026
Thought-provoking topic: Publication pollution: The erosion of research ethics in the age of metrics www.ovid.com/jnls/jehp/fu...
ovid.com
Publication pollution: The erosion of research... : Journal of Education and Health Promotion
Abstract was not provided for this article.
132
Erick Turner @eturnermd1.bsky.social · 28/08/2026
TrialScout links published results to trial registrations using a large language model An important contribution toward eradicating publication bias by @ndevito1.bsky.social and colleagues! linkinghub.elsevier.com/retrieve/pii...
010
Erick Turner @eturnermd1.bsky.social · 14/07/2026
TLDR: Strength of evidence for efficacy of gepirone ER for major depressive disorder... Based on published clinical trials: B/B+ Based on clinical trial data in FDA reviews: D+
110
Erick Turner @eturnermd1.bsky.social · 11/07/2026
Trying out AI to see what it says about the subject of our recent @jamapsychiatry.com paper, gepirone ER. I asked OpenEvidence to give it a grade for the level of evidence. Its initial response ⬇️
100
Erick Turner @eturnermd1.bsky.social · 11/07/2026
Reason to hope for a more transparent FDA: "A proposed rule planned for October would end the “longstanding presumption” that an unapproved application’s existence is confidential, enabling proactive disclosure of complete response letters, the agency’s unified agenda states." Fingers crossed!🤞
101
Reposted by Erick Turner
MedPage Today @medpagetoday.com · 29/06/2026
What we heard this week ⬇️👀 #MedSky "I said, 'Wait a minute. Isn't this the same drug?'" -- @eturnermd1.bsky.social, of @ohsunews.bsky.social, discussing the FDA's approval of a depression drug that had more negative than positive studies. www.medpagetoday.com/publichealth...
medpagetoday.com
How a Drug With More Negative Than Positive Studies Won FDA Approval
Researchers urge inclusion of negative studies on drug labels
122
Erick Turner @eturnermd1.bsky.social · 24/06/2026
Happy to report that a paper of ours is out today in JAMA Psychiatry. Many thanks to co-authors @akesselheim.bsky.social, John Powers, and Rosa Ahn-Horst. The FDA’s job is to approve “effective” drugs, but what does that mean exactly? pubmed.ncbi.nlm.nih.gov/42340691/
164
Erick Turner @eturnermd1.bsky.social · 19/06/2026
Recently published study on reporting bias, led by @vipsmdmed.bsky.social. I might be missing something, but I'm surprised that a couple of these high-impact journals were publishing negative studies at rates of ~50%, higher than I would have expected. pmc.ncbi.nlm.nih.gov/articles/PMC...
122
Erick Turner @eturnermd1.bsky.social · 06/06/2026
Nick @ndevito1.bsky.social, a question for you. In ur 2020 Lancet pub www.thelancet.com/journals/lan..., ~41% of trials had reported results w/in the 1-yr deadline. OTOH ur TrialsTracker fdaaa.trialstracker.net shows a % reported = 79%. Have things improved that much or R the methods different?
thelancet.com
Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study
Compliance with the FDAAA 2007 is poor, and not improving. To our knowledge, this is the first study to fully assess compliance with the Final Rule of the FDAAA 2007. Poor compliance is likely to refl...
100
Erick Turner @eturnermd1.bsky.social · 06/06/2026
"These findings suggest that longstanding concerns regarding publication bias in CAM publishing have not diminished over time and appear to have intensified..." Reports of positive outcomes have ~doubled, while reports of negative findings remain ~nonexistent. pubmed.ncbi.nlm.nih.gov/42249414/
044
Erick Turner @eturnermd1.bsky.social · 12/05/2026
Reminds me of thus old Far Side cartoon.
020
Erick Turner @eturnermd1.bsky.social · 12/05/2026
The latest episode of the FDA soap opera... F.D.A. Commissioner Marty Makary Resigns After Weeks of Pressure www.nytimes.com/2026/05/12/u...
nytimes.com
F.D.A. Commissioner Marty Makary Resigns After Weeks of Pressure
120
Erick Turner @eturnermd1.bsky.social · 09/05/2026
This article's title says it all ⬇️ www.theguardian.com/us-news/2026...
theguardian.com
‘The FDA is a complete mess’: Trump makes fate of agency chief unclear as public trust plummets
Food and Drug Administration commissioner’s decisions have hurt staff morale and put his job in crosshairs
000
Erick Turner @eturnermd1.bsky.social · 28/04/2026
The FDA has announced a new initiative. Given the FDA's history, the cynic in me suspects that this idea of "real-time clinical trials" is designed to lower the bar for industry (again). (cont'd) www.fda.gov/news-events/...
221
Erick Turner @eturnermd1.bsky.social · 20/04/2026
More evidence of the pervasiveness of publication bias. Article: "Publication Bias in Coronary Artery Disease Clinical Trials: A Bibliometric Review" pubmed.ncbi.nlm.nih.gov/41999643/ "The publication rate for positive studies was 92%, whereas for negative studies it was 50% (P<0.001)."
131
Erick Turner @eturnermd1.bsky.social · 19/04/2026
Psychedelic drug policy via podcaster influence. @garyschw.bsky.social, quoting @statnews.com: "Rogan said he texted Trump about research around ibogaine, and the president’s response was quick: 'Sounds great. Do you want FDA approval? Let’s do it.'" garyschwitzer.substack.com?utm_campaign...
213
Erick Turner @eturnermd1.bsky.social · 19/04/2026
Hopefully we'll C some teeth following this overly gentle "reminder". This FDA bulletin www.fda.gov/news-events/... mentions a Mar 30 message to trial sponsors intended to "provide...the opportunity to comply", hinting at poss "further regulatory action". Nice, but the FDA need not B so obsequious.
fda.gov
FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
The U.S. Food and Drug Administration has reminded more than 2,200 medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials....
020
Erick Turner @eturnermd1.bsky.social · 16/04/2026
This guy picked up nearly $4000 worth of "goodies" at a dermatology conference. Multiply that by thousands of conference attendees. Yet only a fraction of what these companies spend on marketing. Just witness the plethora of ads for very expen$I've derm drugs on TV www.tiktok.com/@dr.michaelp...
tiktok.com
you’ll never guess the total cost 😅 AAD dermatology conference skincare haul
TikTok video by Michael Park, MD
010
Erick Turner @eturnermd1.bsky.social · 15/04/2026
www.doximity.com/newsfeed/c46...
doximity.com
Judge tosses lawsuit over controversial Paxil ‘Study 329’
A judge has dismissed a legal challenge aimed at forcing Elsevier to retract a long-criticized study that concluded the antidepressant Paxil was safe and effective for teens. The 2001 paper, publis…
000
Erick Turner @eturnermd1.bsky.social · 13/04/2026
F.D.A. Pushes Drug Developers to Report Clinical Trial Results www.nytimes.com/2026/04/13/w...
nytimes.com
F.D.A. Pushes Drug Developers to Report Clinical Trial Results
121
Erick Turner @eturnermd1.bsky.social · 24/03/2026
www.cspi.org/press-releas...
cspi.org
Now is the time to act on 32 FDA transparency reforms, experts say in JAMA
000
Erick Turner @eturnermd1.bsky.social · 17/03/2026
BMJ Open article: "Substantial undisclosed financial COIs were identified among the top 10 earners in high-impact psychiatry journals." bmjopen.bmj.com/content/15/1...
bmjopen.bmj.com
Undisclosed financial conflicts of interest among physician-authors in leading US psychiatry journals: a cross-sectional study
Objective To assess the prevalence and magnitude of undisclosed financial conflicts of interest (COIs) among physician-authors in high-impact US-based psychiatry journals. Design Cross-sectional stud...
045
Erick Turner @eturnermd1.bsky.social · 07/03/2026
Vinay Prasad resigns from the FDA. Well, he did resign in August but was brought back in a few days, but maybe this time it's for real. www.nytimes.com/2026/03/06/h...
nytimes.com
Divisive F.D.A. Vaccine Regulator Resigns
330
Erick Turner @eturnermd1.bsky.social · 06/03/2026
Makary apparently wants his FDA reviewers to be about as thorough as the "security guard" in this meme.
media.tenor.com
a man in a green and blue jacket stands next to another man
ALT: a man in a green and blue jacket stands next to another man
000
Erick Turner @eturnermd1.bsky.social · 27/02/2026
Hey, here's a thought... How about offering bonus payments for staffers who complete CORRECT reviews and recommend approval ONLY if the drugs are truly safe and effect?
160
Erick Turner @eturnermd1.bsky.social · 27/02/2026
apnews.com/article/drug... to offer bonus payments to staffers who complete speedy drug reviews
apnews.com
FDA to offer bonus payments to staffers who complete speedy drug reviews
The head of the Food and Drug Administration plans to start offering bonus payments to agency drug reviewers who complete their work ahead of the schedule.
000
Reposted by Erick Turner
Beth S Linas, PhD, MHS @bethlinas.bsky.social · 19/02/2026
This could be extremely harmful. False positives, power issues, & rare adverse events come to mind if there is only one trial required 🤦‍♀️
apnews.com
FDA will drop two-study requirement for new drug approvals, aiming to speed access
The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals.
43017
Erick Turner @eturnermd1.bsky.social · 05/02/2026
STAT piece first-authored be @lizzylawrence.bsky.social. Perhaps she has insight into the politics. I can’t imagine RFK Jr NOT supporting a psychedelic, so was this a defeat for him? (Apologies if this is addressed in the full text of the article, but I lack access.)
221
Erick Turner @eturnermd1.bsky.social · 05/02/2026
It seems that decisions at the FDA can go either way based on a combination of science and politics. www.statnews.com/2026/02/04/p...
statnews.com
Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment
Trump administration officials vetoed the FDA's plan to fast-track the review of a psychedelic treatment for severe depression, STAT has learned.
142
Erick Turner @eturnermd1.bsky.social · 27/01/2026
Article: Missing data about missing tissue ⬇️ dx.plos.org/10.1371/jour...
dx.plos.org
Missing tissue, missing data: Resolving brain volume loss caused by anti-amyloid therapies
Anti-amyloid drugs modestly slow Alzheimer’s disease progression, albeit with uncertainty of sustained benefit, particularly as they cause paradoxical acceleration of brain volume changes. Here, we ex...
010
Erick Turner @eturnermd1.bsky.social · 03/01/2026
Nice article, providing an overview of the various types of spin: Although the article relates spin to research on acupuncture, it applies to research in general. www.sciencedirect.com/science/arti...
sciencedirect.com
Misleading Readers without Lies: Understanding Spin and its Relevance to Acupuncture Research
This article provides an overview of spin in general and the current state of spin research in acupuncture studies. We introduce the definition and hi…
040
Erick Turner @eturnermd1.bsky.social · 31/12/2025
This “stellar groups” has a North Star…@floriannaudet.bsky.social An honor to be helping shine some additional light!
232
Erick Turner @eturnermd1.bsky.social · 21/12/2025
Just saw a news item abt this article in Nature www.nature.com/articles/s41.... Glad 2 see that the authors provided (or the reviewers insisted) that the figure w the primary outcome results show the full range of scores, showing not only the treatment effect but also how much was NOT treated (lots)
121
Erick Turner @eturnermd1.bsky.social · 15/12/2025
More from the FDA soap opera. I don't subscribe to the (very expensive) Pink Sheet, so apologies for the teaser. "As diff's emerged betw FDA staff & senior political leaders over its COVID-19 safety review, CBER Dir Vinay Prasad added an old colleague & critic of COVID-19 policy 2 the center."
110
Erick Turner @eturnermd1.bsky.social · 15/12/2025
garyschwitzer.substack.com/p/comparing-...
garyschwitzer.substack.com
Comparing stories on the new "souped-up" GLP-1 drug
You can report on the positive findings but don't bury the side effects
010
Erick Turner @eturnermd1.bsky.social · 15/12/2025
open.substack.com/pub/youcankn...
open.substack.com
Do dogs cause autism?
The anatomy of an unfalsifiable hypothesis
031
Erick Turner @eturnermd1.bsky.social · 05/12/2025
Right, there's the weird split screen going on. They seem to want to make it harder to get vaccines approved but easier to get drugs approved.
media.tenor.com
a man in a suit and tie says are you making any sense of this snl
ALT: a man in a suit and tie says are you making any sense of this snl
000
Erick Turner @eturnermd1.bsky.social · 05/12/2025
Most people have been surprised upon learning that you only need 2 positive clinical trials to get approved. Wait till they hear that now you need only one!
122
Reposted by Erick Turner
Holly Fernandez Lynch @hollylynchez.bsky.social · 02/12/2025
Story now updated w/ the answer: "Three sources close to Pazdur told STAT that concerns about the legality of a new drug review program, Makary and Prasad inserting themselves into drug review decisions, and Makary’s efforts to handpick hires for CDER contributed to Pazdur’s decision to leave."
0129
Erick Turner @eturnermd1.bsky.social · 02/12/2025
The latest episode of the FDA soap opera ⬇️ Convenient summary of the preceding episodes along the right side. 🙄
010
Erick Turner @eturnermd1.bsky.social · 29/11/2025
Proud to have been a member of @floriannaudet.bsky.social's team. Great to see this out!
061
Reposted by Erick Turner
de’on @justkeepskeeting.pro · 25/11/2025
this is mesmerizing
4748001787
Erick Turner @eturnermd1.bsky.social · 21/11/2025
041
Erick Turner @eturnermd1.bsky.social · 12/11/2025
Maybe I should start numbering these soap opera "episodes". Pazdur JUST turned down the offer to be CDER Director. Now he accepts. Negotiating tactic?
010
Erick Turner @eturnermd1.bsky.social · 10/11/2025
Today's episode of the FDA soap opera. First, Tidmarsh leaves, then Pazdur and Thanh Hai say no thanks to the "opportunity" to be CDER Director, and now they're asking for "anyone interested" to apply. 🙄 @akesselheim.bsky.social
010
Erick Turner @eturnermd1.bsky.social · 09/11/2025
I like what the authors have done here...apply EBM principles to a specific drug class. This brings it to the attention of specialty physicians whose radar screens don't normally cover 'meta' topics like EBM. pubmed.ncbi.nlm.nih.gov/41198383/
010
Erick Turner @eturnermd1.bsky.social · 03/11/2025
Latest episode of the FDA soap opera www.nytimes.com/2025/11/02/h...
nytimes.com
F.D.A. Drug Unit Chief Resigns, and Is Sued by Drug Company
010